Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease

BMC Neurology

Volumn 2, Issue , 2002, Pages

  Moore, David F ^a   Altarescu, Gheona ^a   Herscovitch, Peter ^b   Schiffmann, Raphael ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AGALSIDASE ALFA; ALPHA GALACTOSIDASE; PLACEBO; WATER; CARBONATE DEHYDRATASE INHIBITOR; DIAGNOSTIC AGENT; OXYGEN;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ENZYME REPLACEMENT; FABRY DISEASE; HEART DISEASE; HEMIZYGOSITY; HUMAN; INFUSION SYSTEM; KIDNEY FAILURE; LIPIDOSIS; MALE; MORBIDITY; MORTALITY; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME; VISUAL STIMULATION; X CHROMOSOME LINKED DISORDER; BRAIN; BRAIN CIRCULATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTOSTIMULATION; PHYSIOLOGY; REFERENCE VALUE; SCINTISCANNING; STATISTICS; VASCULARIZATION; VISUAL CORTEX;

ACETAZOLAMIDE; ADULT; ALPHA-GALACTOSIDASE; BRAIN; CARBONIC ANHYDRASE INHIBITORS; CEREBROVASCULAR CIRCULATION; FABRY DISEASE; HUMANS; MALE; MIDDLE AGED; OXYGEN RADIOISOTOPES; PHOTIC STIMULATION; RANDOMIZED CONTROLLED TRIALS; REFERENCE VALUES; TOMOGRAPHY, EMISSION-COMPUTED; VISUAL CORTEX;

EID: 0013155111     PISSN: 14712377     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2377-2-4     Document Type: Article

References (29)

1. Brady R, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L: Enzymatic defect in Fabry disease: ceramide trihexosidase deficiency. N Engl J Med 1967, 276:1163-1167
2. Kint J: Alpha-galactosidase deficiency. Science 1970, 167:1268
3. Kanda A, Nakao S, Tsuyama S, Murata F, Kanzaki T: Fabry disease: ultrastructural lectin histochemical analyses of lysosomal deposits. Virchows Arch 2000, 436:36-42
4. Desnick R, Ioannou YA, Eng CM: α-Galactosidase A Deficiency: Fabry Disease. Valle. (Edited by: R Charles, Scriver, Arthur L, Beaudet William, S Sly David) New York, McGraw-Hill 2001, 3733-3774
5. Moore DF, Scott LJC, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, Pease-Fye M, Ferri R, Brady RO, Herscovitch P, Schiffmann R: Regional Cerebral Hyper-Perfusion and Nitric Oxide Pathway Dysregulation in Fabry Disease: Reversal by Enzyme Replacement Therapy. Circulation 2001, 104:1506-1512
6. Schiffmann R, Kopp J, Austin H, Sabnis S, Moore DF, Weibel T, Balow J, Brady RO: A randomized double-blind, placebo-controlled trial of enzyme replacement therapy in Fabry disease. JAMA 2001, 285:2743-2749
7. Mitsias P, Levine SR: Cerebrovascular complications of Fabry's disease. Ann Neurol 1996, 40:8-17
8. Evans O, Parker CC, Haas RH, Naidu S, Moser H, Bock HGO: " Inborn errors of metabolism of the nervous system. Chapter 68, Neurology in Clinical Practice., " Butterworth-Heinemann, Woburn, MA, ed. Third Edition, 2000
9. Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, Bryant M, Panza JA, Schiffmann R: Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 2001, 32:1559-1562
10. Moore DF, Herscovitch P, Schiffmann R: Selective arterial distribution of cerebral hyper-perfusion in Fabry disease. J. Neuroimaging 2001, 11:303-307
11. Crutchfield K, Patronas NJ, Dambrosia JM, Frei KP, Banerjee TK, Barton NW, Schiffmann R: Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998, 50:1746-1749
12. Fox P, Raichle ME: Stimulus rate determines regional brain blood flow in the striate cortex. Ann Neurol 1985, 17:303-305
13. Herscovitch P, Markham J, Raichle ME: Brain blood flow measured with intravenous O-15 water. Theory and error analysis. J Nucl Med 1983, 24:782-789
14. Koeppe R, Holden JE, Polcyn RE, Nickles RJ, Hutchins GD, Weese JL: Performance comparison of parameter estimation techniques for the quantitation of local cerebral blood flow by dynamic positron computed tomography. J Cereb Blood Flow Metab 1985, 5:214-223
15. Collins D, Zijdenbos AP, Kollokian JG, Kabani NJ, Holmes CJ, Evans AC: Design and construction of a realistic digital brain phantom. IEEE Transactions on Medical Imaging 1998, 17:463-469
16. Friston K, Ashburner J, Frith CD, Poline JB, Heather JD, Frackowiak RSJ: Spatial registration and normalization of images. Human Brain Mapping 1995, 2:165-189
17. Nowinski W, Bryan RN, Raghavan R: The Electronic Clinical Brain Atlas. New YorK, Thieme. 1999
18. Faraci F, Heistad DD: Regulation of the Cerebral Circulation: Role of Endothelium and Potassium Channels. Physiological Reviews 1998, 78:53-97
19. Szabo C: Physiological and pathophysiological roles of nitric oxide in the central nervous system. Brain Research Bulletin 1996, 41:131-141
20. Inao S, Tadokoro M, Nishino M, Mizutani N, Terada K, Bundo M, Kuchiwaki H, Yoshida J: Neural Activation of the Brain with Hemodynamic Insufficiency. J Cereb Blood Flow Metab 1998, 18:960-967
21. Dahl A, Russell D, Rootwell K, Nyber-Hansen R, Kerty E: Cerebral vasoreactivity assessed with transcranial Doppler and regional cerebral blood flow measurements. Dose, serum concentration, and time course of the response to acetazolamide. Stroke 1995, 26:2302-2306
22. 15O-water measurements. Nuclear Medicine Communications 1996, 17:1047-1051
23. Kiss B, Dallinger S, Findl O, Rainer G, Eichler HG, Schmetterer L: Acetazolamide-induced cerebral and ocular vasodilation in humans is independent of nitric oxide. Am. J. Physiol 1999, 276:R1661-R1667
24. White R, Deane C, Vallance P, Markus HS: Nitric Oxide Synthase Inhibition in Humans Reduces Cerebral Blood Flow but Not the Hyperemic Response to Hypercapnia. Stroke 1998, 29:467-472
25. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H, Kneitz B, Lagaud G, Christ GJ, Edelmann W, Lisanti MP: Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. Journal of Biological Chemistry 2001, 276:38121-38138
26. Razani B, Lisanti MP: Caveolin-deficient mice: insights into caveolar function and human disease. Journal of Clinical Investigation 2001, 108:1553-1561
27. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000, 87:840-844
28. Wei E, Christman CW, Kontos HA, Povlishock JT: Effects of oxygen radicals on cerebral arterioles. Am J Physiol 1985, 248:H157-H162
29. Etchevers H, Vincent C, Le Dourarin NM, Couly GF: The cephalic neural crest provides pericytes and smooth muscle cells to all blood vessels of the face and forebrain. Development 2001, 128:1059-1068